Get the Stockscreener App
0.73
0.82%
-0.006
After Hours:
.71
-0.02
-2.74%
Glucotrack Inc stock is traded at $0.73, with a volume of 571.18K.
It is down -0.82% in the last 24 hours and down -15.12% over the past month.
GlucoTrack Inc is a medical device company focused on the development of an implantable continuous blood glucose monitor (CBGM) for patients with Type 1 and Type 2 diabetes. The company is developing its Glucotrack CBGM system to provide continuous glucose monitoring using implantable sensor technology and is advancing the product through clinical studies and regulatory processes.
See More
Previous Close:
$0.736
Open:
$0.7
24h Volume:
571.18K
Relative Volume:
0.21
Market Cap:
$2.67M
Revenue:
-
Net Income/Loss:
$-19.39M
P/E Ratio:
-0.0386
EPS:
-18.9115
Net Cash Flow:
$-15.34M
1W Performance:
-12.78%
1M Performance:
-15.12%
6M Performance:
-87.89%
1Y Performance:
+295.88%
1-Day Range:
$0.68
$0.7357
1-Week Range:
$0.68
$1.28
52-Week Range:
$0.0927
$15.90
Glucotrack Inc Stock (GCTK) Company Profile
Name
Glucotrack Inc
Sector
Industry
Phone
972 (8) 675-7878
Address
301 RT 17 NORTH, RUTHERFORD
Compare GCTK vs ISRG, BDX, MDLN, ALC, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GCTK
Glucotrack Inc
|
0.73 | 2.69M | 0 | -19.39M | -15.34M | -18.91 |
ISRG
Intuitive Surgical Inc
|
451.38 | 160.21B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.17 | 41.62B | 21.92B | 1.76B | 2.63B | 6.1223 |
MDLN
Medline Inc
|
45.32 | 37.37B | 28.43B | 1.16B | 1.26B | 1.4457 |
ALC
Alcon Inc
|
74.45 | 35.82B | 10.40B | 980.00M | 1.61B | 1.9749 |
RMD
Resmed Inc
|
207.88 | 30.38B | 5.40B | 1.49B | 1.78B | 10.12 |
Glucotrack Inc Stock (GCTK) Latest News
GlucoTrack Executes Debt-for-Equity Exchange and Investor Update - The Globe and Mail
Peer-Reviewed Study in Journal of Diabetes Research Verifies Glucotrack’s Long‑Term Continuous Blood Glucose Monitoring Technology - citybiz
[EFFECT] Glucotrack, Inc. SEC Filing - Stock Titan
Glucotrack (NASDAQ: GCTK) swaps $988K debt for 1.3M new shares - Stock Titan
GlucoTrack Reports Strong Preclinical Data for Implantable CBGM - TipRanks
Peer-reviewed CBGM data back Glucotrack (NASDAQ: GCTK) IDE plans - Stock Titan
Glucotrack publishes 240-day glucose monitor study results - Investing.com
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology - The Manila Times
An implantable glucose monitor held accuracy for 240 days in animal study - Stock Titan
Glucotrack, Inc. (NASDAQ: GCTK) registers 20.06M shares tied to $20M financing - Stock Titan
GCTK Stock Chops Higher As GlucoTrack Marks Key CGM Milestones - StocksToTrade
GCTK Stock Pops As GlucoTrack Marks Key CGM Milestones - timothysykes.com
GlucoTrack stock gains as data backs FDA filing plans for glucose monitoring tech - MSN
GCTK stock is soaring pre-market today — what is fueling the surge? - MSN
GCTK Stock Price, Quote & Chart | GLUCOTRACK INC (NASDAQ:GCTK) - ChartMill
GlucoTrack Stock Short Interest Falls to 73.9% - Quiver Quantitative
GlucoTrack files to sell 20.06M shares of common stock by selling shareholders - MSN
GCTK GlucoTrack lays out new commercial growth plans in its latest quarterly earnings release for non-invasive glucose monitors.Dividend Report - Cổng thông tin điện tử tỉnh Tây Ninh
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant - Yahoo Finance
GlucoTrack announces publication of peer-reviewed article on glucose sensors - TipRanks
New Peer-Reviewed Study Supports Glucotrack’s Long-Duration Implantable Continuous Blood Glucose Monitoring Technology - citybiz
Glucotrack publishes peer-reviewed study on glucose sensor stability - Investing.com
Glucotrack publishes peer-reviewed study on glucose sensor stability By Investing.com - Investing.com Canada
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology - marketscreener.com
One-year lab test backs Glucotrack implantable glucose monitor - Stock Titan
GlucoTrack (GCTK) Stock Investment Today (Volatility Increases) 2026-04-20Turnaround Stocks - Cổng thông tin điện tử tỉnh Lào Cai
GCTK | GlucoTrack, Inc. Common Stock Insider Trading - Quiver Quantitative
GlucoTrack (GCTK) Stock Volume Drop (Smart Money Active) 2026-04-18Shared Buy Zones - Newser
Should You Hold GlucoTrack (GCTK) Stock? (Technical Weakness) 2026-04-16Momentum Signals - Cổng thông tin điện tử tỉnh Lào Cai
GlucoTrack Executes Debt-for-Equity Exchange to Reduce Obligations - The Globe and Mail
Glucotrack exchanges $600,000 note for 895,000 shares with investor By Investing.com - Investing.com
Glucotrack Swaps $600,000 Note Portion for 895,000 Shares Under Exchange Agreement - TradingView
Glucotrack (NASDAQ: GCTK) swaps $600K debt for 895,000 shares - Stock Titan
Technical Analysis: Is GlucoTrack Inc impacted by rising ratesProduct Launch & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
$Glucotrack (GCTK.US)$ thanks market - Moomoo
RSI Check: Will GlucoTrack Inc benefit from geopolitical trends2026 Intraday Action & Weekly High Return Stock Forecasts - baoquankhu1.vn
Glucotrack reports net loss of USD 19.4M in FY 2025 - Medical Buyer
Glucotrack, Inc. 2025 Annual Report – Implantable Continuous Blood Glucose Monitor Development, Regulatory Progress, and Risk Factors 66 - Minichart
GCTK: Improved net loss and cash position support 2026 clinical trial launch for implantable CBGM - TradingView — Track All Markets
Glucotrack (GCTK) advances implantable CBGM but flags going concern risk - Stock Titan
GlucoTrack, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Glucotrack (NASDAQ: GCTK) trims 2025 loss and readies IDE for implantable CBGM trials - Stock Titan
Glucotrack, Inc. Announces IDE Filing Plans for Continuous Blood Glucose Monitoring Technology and Patents Issued by USPTO - Quiver Quantitative
Glucotrack’s 3-year glucose implant targets a U.S. human trial in 2026 - Stock Titan
Technical Analysis: What analysts say about GlucoTrack Inc stock2026 Analyst Calls & Low Drawdown Trading Techniques - baoquankhu1.vn
GlucoTrack Plummets 27%: Is This the Bottom of a Deep Downtrend? A High-Stakes Analysis for 2026 - Bitget
GCTK PE Ratio & Valuation, Is GCTK Overvalued - Intellectia AI
GlucoTrack, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Glucotrack Inc Stock (GCTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):